41 results on '"Del Monte-Millán M"'
Search Results
2. Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience
- Author
-
Pérez Ramírez, S., del Monte-Millán, M., López-Tarruella, S., Martínez Jáñez, N., Márquez-Rodas, I., Lobo Samper, F., Izarzugaza Perón, Y., Rubio Terres, C., Rubio Rodríguez, D., García-Sáenz, J. Á., Moreno Antón, F., Zamora Auñón, P., Arroyo Yustos, M., Lara Álvarez, M. Á., Ciruelos Gil, E. M., Manso Sánchez, L., Echarri González, M. J., Guerra Martínez, J. A., Jara Sánchez, C., Bueno Muiño, C., García Adrián, S., Carrión Galindo, J. R., Valentín Maganto, V., and Martín, M.
- Published
- 2020
- Full Text
- View/download PDF
3. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series
- Author
-
Picornell, A. C., Echavarria, I., Alvarez, E., López-Tarruella, S., Jerez, Y., Hoadley, K., Parker, J. S., del Monte-Millán, M., Ramos-Medina, R., Gayarre, J., Ocaña, I., Cebollero, M., Massarrah, T., Moreno, F., García Saenz, J. A., Gómez Moreno, H., Ballesteros, A., Ruiz Borrego, M., Perou, C. M., and Martin, M.
- Published
- 2019
- Full Text
- View/download PDF
4. 216P Relationship between regulatory T lymphocytes (Treg): Related genes and pathological response to neoadjuvant docetaxel-carboplatin in early-stage triple-negative breast cancer (TNBC)
- Author
-
Martín Lozano, R., Roche-Molina, M., Alvarez, E., Del Monte-Millan, M., Jerez Gilarranz, Y., Moreno Anton, F., García Saenz, J.Á., Echavarria Diaz-Guardamino, I., Massarrah, T., Cebollero, M., Ballesteros Garcia, A.I., Bohn Sarmiento, U., Gomez Moreno, H.L., Fuentes, H.A., Herrero Lopez, B., Gamez Casado, S., Bueno Muiño, C., Bueno, O., Lopez-Tarruella Cobo, S., and Martin Jimenez, M.
- Published
- 2022
- Full Text
- View/download PDF
5. Review: circulating tumor cells in the practice of breast cancer oncology
- Author
-
Ramos-Medina, R., Moreno, F., Lopez-Tarruella, S., del Monte-Millán, M., Márquez-Rodas, I., Durán, E., Jerez, Y., Garcia-Saenz, J. A., Ocaña, I., Andrés, S., Massarrah, T., González-Rivera, M., and Martin, M.
- Published
- 2016
- Full Text
- View/download PDF
6. 85P Correlation between nCOUNTER PAM-50 assay and three IHC-based surrogate intrinsic breast cancer subtype classifiers: A real-world study
- Author
-
Martín, M., primary, Del Monte-Millán, M., additional, Jerez, Y., additional, Echavarria Diaz-Guardamino, I., additional, Herrero Lopez, B., additional, Gamez Casado, S., additional, Roche-Molina, M., additional, Marquez-Rodas, I., additional, Cebollero, M., additional, Alvarez, E., additional, Massarrah, T., additional, Ocaña, I., additional, Arias, A., additional, García Saenz, J.Á., additional, Moreno Anton, F., additional, Olier Garate, C., additional, Moreno Muñoz, D., additional, Marrupe Gonzalez, D., additional, Merina, T., additional, and Lopez-Tarruella Cobo, S., additional
- Published
- 2022
- Full Text
- View/download PDF
7. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
- Author
-
Gottipati, S., Earl, H.M., Yau, C., Cameron, D.A., Abraham, J., Hayward, L., Reyal, F., Osdoit, M., Sonke, G.S., Wesseling, J., Boughey, J., Goetz, M.P., DeMichele, A., Pusztai, L., Sharma, P., Jimenez, M. Martin, Lopez-Tarruella Cobo, S., Del Monte-Millan, M., Symmans, F., and Mukhtar, R.
- Published
- 2023
- Full Text
- View/download PDF
8. 233P Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital
- Author
-
Bringas Beranek, M., Echavarria Diaz-Guardamino, I., Polo, C., Flores Sanchez, C., Munoz Martin, A.J., Ortega Morán, L., Herrero Lopez, B., Calvo Ferrandiz, P.A., Jerez Gilarranz, Y., Torres Perez-Solero, G., Lopez-Tarruella Cobo, S., Gamez Casado, S., Perez Ramirez, S., Veiga Fernández, A., Pajares, J.A., Sanz, M., Suarez, J., Del Monte-Millan, M., Martin Jimenez, M., and Marquez-Rodas, I.
- Published
- 2023
- Full Text
- View/download PDF
9. 1654P Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
- Author
-
Gutierrez Alonso, N., Benavente, M., Bringas Beranek, M., Soto Alsar, J., Palma, M., Cañete Muñoz, M.A., Lopez Alfonso, A., Rahimi Mousavi, P., Roche-Molina, M., Del Monte-Millan, M., Megias, D., García Pérez, Á., Mullor Delgado, L.A., Ortega Morán, L., Torres Perez-Solero, G., Morón, B.I., Calvo Ferrandiz, P.A., García Alfonso, P., Martin Jimenez, M., and Munoz Martin, A.J.
- Published
- 2023
- Full Text
- View/download PDF
10. 1648P Association between circulating tumor cell count and thrombosis in pancreatic cancer
- Author
-
Benavente, M., Gutierrez Alonso, N., Bringas Beranek, M., Soto Alsar, J., Palma, M., Cañete Muñoz, M.A., López Jiménez, C., Gutierrez Ortiz, A., Juliao Caamaño, D.S., Lopez Alfonso, A., Ortega Morán, L., Torres Perez-Solero, G., Megias, D., Calvo Ferrandiz, P.A., Del Monte-Millan, M., Rahimi Mousavi, P., Roche-Molina, M., García Alfonso, P., Martin Jimenez, M., and Munoz Martin, A.J.
- Published
- 2023
- Full Text
- View/download PDF
11. 141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel
- Author
-
Echavarria Diaz-Guardamino, I., Lopez-Tarruella Cobo, S., Del Monte-Millan, M., Alvarez, E., Jerez, Y., Moreno Anton, F., García Saenz, J.Á., Massarrah, T., Ocaña, I., Cebollero, M., Ballesteros Garcia, A.I., Bohn Sarmiento, U., Gomez, H., Fuentes, H.A., Herrero Lopez, B., Gamez Casado, S., Bueno, O., Jiménez-Santos, M.J., Roche-Molina, M., and Martin Jimenez, M.
- Published
- 2022
- Full Text
- View/download PDF
12. Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience
- Author
-
Pérez Ramírez, S., primary, del Monte-Millán, M., additional, López-Tarruella, S., additional, Martínez Jáñez, N., additional, Márquez-Rodas, I., additional, Lobo Samper, F., additional, Izarzugaza Perón, Y., additional, Rubio Terres, C., additional, Rubio Rodríguez, D., additional, García-Sáenz, J. Á., additional, Moreno Antón, F., additional, Zamora Auñón, P., additional, Arroyo Yustos, M., additional, Lara Álvarez, M. Á., additional, Ciruelos Gil, E. M., additional, Manso Sánchez, L., additional, Echarri González, M. J., additional, Guerra Martínez, J. A., additional, Jara Sánchez, C., additional, Bueno Muiño, C., additional, García Adrián, S., additional, Carrión Galindo, J. R., additional, Valentín Maganto, V., additional, and Martín, M., additional
- Published
- 2019
- Full Text
- View/download PDF
13. Activity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients
- Author
-
Martín, M., primary, Ramos-Medina, R., additional, Garcia Sáenz, J.Á., additional, del Monte-Millán, M., additional, Cebollero, M., additional, Moreno, F., additional, Echavarria, I., additional, Jerez, Y., additional, Massarrah, T., additional, and Lopez-Tarruella Cobo, S., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms
- Author
-
Picornell, A.C., primary, Echavarria Diaz-Guardamino, I., additional, Alvarez Castillo, E.L., additional, Lopez-Tarruella Cobo, S., additional, Jerez, Y., additional, Hoadley, K., additional, Parker, J., additional, del Monte-Millán, M., additional, Ramos Medina, R., additional, Gayarre, J., additional, Ocaña, I., additional, Cebollero, M., additional, Massarrah, T., additional, Moreno Antón, F., additional, García-Saenz, J.A., additional, Gomez Moreno, H., additional, Ballesteros Garcia, A.I., additional, Ruiz Borrego, M., additional, Perou, C., additional, and Martin Jimenez, M., additional
- Published
- 2017
- Full Text
- View/download PDF
15. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4)
- Author
-
Echavarria Diaz-Guardamino, I., primary, Picornell, A.C., additional, López-Tarruella, S., additional, Jerez, Y., additional, Hoadley, K., additional, Alvarez, E., additional, del Monte-Millán, M., additional, Gayarre, J., additional, Ramos-Medina, R., additional, Massarrah, T., additional, Ocaña, I., additional, Cebollero, M., additional, Moreno Antón, F., additional, García-Saenz, J.A., additional, Gomez Moreno, H., additional, Fuentes, H., additional, Ballesteros Garcia, A.I., additional, Bohn Sarmiento, U., additional, Perou, C., additional, and Martin Jimenez, M., additional
- Published
- 2017
- Full Text
- View/download PDF
16. Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: A retrospective study in Spanish population
- Author
-
Perez Ramirez, S., primary, del Monte-Millán, M., additional, López-Tarruella, S., additional, Márquez-Rodas, I., additional, Jerez, Y., additional, Lobo Samper, F., additional, Izarzugaza Peron, Y., additional, Martínez Jañez, N., additional, García-Saenz, J.A., additional, Moreno Antón, F., additional, Zamora Auñón, P., additional, Arroyo Yustos, M., additional, Lara Álvarez, M.Á., additional, Ciruelos Gil, E.M., additional, Manso Sánchez, L., additional, Echarri González, M.J., additional, Guerra Martínez, J.A., additional, Jara Sánchez, C., additional, Valentín Maganto, V., additional, and Martin Jimenez, M., additional
- Published
- 2017
- Full Text
- View/download PDF
17. Review: circulating tumor cells in the practice of breast cancer oncology
- Author
-
Ramos-Medina, R., primary, Moreno, F., additional, Lopez-Tarruella, S., additional, del Monte-Millán, M., additional, Márquez-Rodas, I., additional, Durán, E., additional, Jerez, Y., additional, Garcia-Saenz, J. A., additional, Ocaña, I., additional, Andrés, S., additional, Massarrah, T., additional, González-Rivera, M., additional, and Martin, M., additional
- Published
- 2015
- Full Text
- View/download PDF
18. 184P - Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: A retrospective study in Spanish population
- Author
-
Perez Ramirez, S., del Monte-Millán, M., López-Tarruella, S., Márquez-Rodas, I., Jerez, Y., Lobo Samper, F., Izarzugaza Peron, Y., Martínez Jañez, N., García-Saenz, J.A., Moreno Antón, F., Zamora Auñón, P., Arroyo Yustos, M., Lara Álvarez, M.Á., Ciruelos Gil, E.M., Manso Sánchez, L., Echarri González, M.J., Guerra Martínez, J.A., Jara Sánchez, C., Valentín Maganto, V., and Martin Jimenez, M.
- Published
- 2017
- Full Text
- View/download PDF
19. 186P - Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms
- Author
-
Picornell, A.C., Echavarria Diaz-Guardamino, I., Alvarez Castillo, E.L., Lopez-Tarruella Cobo, S., Jerez, Y., Hoadley, K., Parker, J., del Monte-Millán, M., Ramos Medina, R., Gayarre, J., Ocaña, I., Cebollero, M., Massarrah, T., Moreno Antón, F., García-Saenz, J.A., Gomez Moreno, H., Ballesteros Garcia, A.I., Ruiz Borrego, M., Perou, C., and Martin Jimenez, M.
- Published
- 2017
- Full Text
- View/download PDF
20. 162PD - Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4)
- Author
-
Echavarria Diaz-Guardamino, I., Picornell, A.C., López-Tarruella, S., Jerez, Y., Hoadley, K., Alvarez, E., del Monte-Millán, M., Gayarre, J., Ramos-Medina, R., Massarrah, T., Ocaña, I., Cebollero, M., Moreno Antón, F., García-Saenz, J.A., Gomez Moreno, H., Fuentes, H., Ballesteros Garcia, A.I., Bohn Sarmiento, U., Perou, C., and Martin Jimenez, M.
- Published
- 2017
- Full Text
- View/download PDF
21. 1584P - Germline genetic background contribution to metastatic dissemination in breast cancer extreme phenotype patients
- Author
-
Santonja, A., Pajares, B., Jiménez-Rodríguez, B., Sousa, C. Fernández-De, Ribelles, N., Lluch-Hernandez, A., Catoira, I., Perez-Ruiz, E., Martin, M., Del Monte-Millan, M., Gonzalez-Neira, A., Pita, G., Pujana, M.A., Ruiz, M., Bonifaci, N., De la Haba, J., Sanchez-Rovira, P., Alba, E., and Romero, A.
- Published
- 2016
- Full Text
- View/download PDF
22. Breast cancer PAM50 signature: Correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series
- Author
-
Ocaña, I., Parker, J.S., Ruiz Borrego, M., López-Tarruella, S., Gómez Moreno, H., Martin, M., Ballesteros, A., Hoadley, K., García Saenz, J.A., Alvarez, E., Del Monte-Millán, M., Moreno, F., Jerez, Y., Perou, C.M., Ramos-Medina, R., Cebollero, M., Echavarria, I., Picornell, A.C., Massarrah, T., and Gayarre, J.
- Subjects
3. Good health - Abstract
Background: Full RNA-Seq is a fundamental research tool for whole transcriptome analysis. However, it is too costly and time consuming to be used in routine clinical practice. We evaluated the transcript quantification agreement between RNA-Seq and a digital multiplexed gene expression platform, and the subtype call after running the PAM50 assay in a series of breast cancer patients classified as triple negative by IHC/FISH. The goal of this study is to analyze the concordance between both expression platforms overall, and for calling PAM50 triple negative breast cancer intrinsic subtypes in particular. Results: The analyses were performed in paraffin-embedded tissues from 96 patients recruited in a multicenter, prospective, non-randomized neoadjuvant triple negative breast cancer trial (NCT01560663). Pre-treatment core biopsies were obtained following clinical practice guidelines and conserved as FFPE for further RNA extraction. PAM50 was performed on both digital multiplexed gene expression and RNA-Seq platforms. Subtype assignment was based on the nearest centroid classification following this procedure for both platforms and it was concordant on 96% of the cases (N = 96). In four cases, digital multiplexed gene expression analysis and RNA-Seq were discordant. The Spearman correlation to each of the centroids and the risk of recurrence were above 0.89 in both platforms while the agreement on Proliferation Score reached up to 0.97. In addition, 82% of the individual PAM50 genes showed a correlation coefficient > 0.80. Conclusions: In our analysis, the subtype calling in most of the samples was concordant in both platforms and the potential discordances had reduced clinical implications in terms of prognosis. If speed and cost are the main driving forces then the preferred technique is the digital multiplexed platform, while if whole genome patterns and subtype are the driving forces, then RNA-Seq is the preferred method.
23. Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.
- Author
-
Martín M, Yoder R, Salgado R, Del Monte-Millán M, Álvarez EL, Echavarría I, Staley JM, O'Dea AP, Nye LE, Stecklein SR, Bueno C, Jerez Y, Cebollero M, Bueno O, García Saenz JÁ, Moreno F, Bohn U, Gómez H, Massarrah T, Khan QJ, Godwin AK, López-Tarruella S, and Sharma P
- Subjects
- Humans, Female, Middle Aged, Adult, Aged, Anthracyclines administration & dosage, Anthracyclines therapeutic use, Prognosis, Neoplasm Staging, Treatment Outcome, Docetaxel administration & dosage, Docetaxel therapeutic use, Carboplatin administration & dosage, Lymphocytes, Tumor-Infiltrating immunology, Neoadjuvant Therapy methods, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms mortality, Triple Negative Breast Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
Purpose: Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in the setting of anthracycline-based chemotherapy. The impact of sTILs on refining outcomes beyond prognostic information provided by pCR in anthracycline-free neoadjuvant chemotherapy (NAC) is not known., Experimental Design: This is a pooled analysis of two studies where patients with stage I (T>1 cm)-III TNBC received carboplatin (AUC 6) plus docetaxel (75 mg/m2; CbD) NAC. sTILs were evaluated centrally on pre-treatment hematoxylin and eosin slides using standard criteria. Cox regression analysis was used to examine the effect of variables on event-free survival (EFS) and overall survival (OS)., Results: Among 474 patients, 44% had node-positive disease. Median sTILs were 5% (range, 1%-95%), and 32% of patients had ≥30% sTILs. pCR rate was 51%. On multivariable analysis, T stage (OR, 2.08; P = 0.007), nodal status (OR, 1.64; P = 0.035), and sTILs (OR, 1.10; P = 0.011) were associated with pCR. On multivariate analysis, nodal status (HR, 0.46; P = 0.008), pCR (HR, 0.20; P < 0.001), and sTILs (HR, 0.95; P = 0.049) were associated with OS. At 30% cut-point, sTILs stratified outcomes in stage III disease, with 5-year OS 86% versus 57% in ≥30% versus <30% sTILs (HR, 0.29; P = 0.014), and numeric trend in stage II, with 5-year OS 93% versus 89% in ≥30% versus <30% sTILs (HR, 0.55; P = 0.179). Among stage II-III patients with pCR, EFS was better in those with ≥30% sTILs (HR, 0.16; P, 0.047)., Conclusions: sTILs density was an independent predictor of OS beyond clinicopathologic features and pathologic response in patients with TNBC treated with anthracycline-free CbD chemotherapy. Notably, sTILs density stratified outcomes beyond tumor-node-metastasis (TNM) stage and pathologic response. These findings highlight the role of sTILs in patient selection and stratification for neo/adjuvant escalation and de-escalation strategies., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
24. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
- Author
-
Lopez-Tarruella S, Del Monte-Millán M, Roche-Molina M, Jerez Y, Echavarria Diaz-Guardamino I, Herrero López B, Gamez Casado S, Marquez-Rodas I, Alvarez E, Cebollero M, Massarrah T, Ocaña I, Arias A, García-Sáenz JÁ, Moreno Anton F, Olier Garate C, Moreno Muñoz D, Marrupe D, Lara Álvarez MÁ, Enrech S, Bueno Muiño C, and Martín M
- Subjects
- Humans, Female, Immunohistochemistry, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Receptor, ErbB-2 genetics, Receptor, ErbB-2 metabolism, Prognosis, Gene Expression Profiling, Receptors, Progesterone genetics, Receptors, Progesterone metabolism, Breast Neoplasms diagnosis, Breast Neoplasms genetics, Breast Neoplasms metabolism
- Abstract
Purpose: Molecular subtyping based on gene expression profiling (i.e., PAM50 assay) aids in determining the prognosis and treatment of breast cancer (BC), particularly in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative tumors, where luminal A and B subtypes have different prognoses and treatments. Several surrogate classifications have been proposed for distinguishing between the luminal A and B subtypes. This study determines the accuracy of local immunohistochemistry (IHC) techniques for classifying HR-positive/HER2-negative (HR+/HER2-) tumors according to intrinsic subtypes using the nCOUNTER PAM50 assay as reference and the HR status definition according the ASCO/CAP recommendations., Methods: Molecular subtypes resulting from nCOUNTER PAM50 performed in our laboratory between 2014 and 2020 were correlated with three different proxy surrogates proposed in the literature based on ER, PR, HER2, and Ki67 expression with different cut-off values. Concordance was measured using the level of agreement and kappa statistics., Results: From 1049 samples with the nCOUNTER test, 679 and 350 were luminal A and B subtypes, respectively. Only a poor-to-fair correlation was observed between the three proxy surrogates and real genomic subtypes as determined by nCOUNTER PAM50. Moreover, 5-11% and 18-36% of the nCOUNTER PAM50 luminal B and A tumors were classified as luminal A and B, respectively, by these surrogates., Conclusion: The concordance between luminal subtypes determined by three different IHC-based classifiers and the nCOUNTER PAM50 assay was suboptimal. Thus, a significant proportion of luminal A and B tumors as determined by the surrogate classifiers could be undertreated or over-treated., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
25. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
- Author
-
Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Massarrah T, Jerez Y, Ayala de la Peña F, García-Sáenz JÁ, Moreno F, Rodríguez-Lescure Á, Malón-Giménez D, Ballesteros García AI, Marín-Aguilera M, Galván P, Brasó-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Paré L, Villacampa G, Prat A, and Martín M
- Subjects
- Female, Humans, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Genomics, Neoadjuvant Therapy methods, Receptor, ErbB-2 genetics, Receptor, ErbB-2 analysis, Retrospective Studies, Trastuzumab therapeutic use, Treatment Outcome, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms pathology
- Abstract
Importance: Biomarkers to guide the use of pertuzumab in the treatment of early-stage ERBB2 (formerly HER2)-positive breast cancer beyond simple ERBB2 status are needed., Objective: To determine if use of the HER2DX genomic assay (Reveal Genomics) in pretreatment baseline tissue samples of patients with ERBB2-positive breast cancer is associated with response to neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab., Design, Setting, and Participants: This is a retrospective diagnostic/prognostic analysis of a multicenter academic observational study in Spain performed during 2018 to 2022 (GOM-HGUGM-2018-05). In addition, a combined analysis with 2 previously reported trials of neoadjuvant cohorts with results from the assay (DAPHNe and I-SPY2) was performed. All patients had stage I to III ERBB2-positive breast cancer, signed informed consent, and had available formalin-fixed paraffin-embedded tumor specimens obtained prior to starting therapy., Exposures: Patients received intravenous trastuzumab, 8 mg/kg, loading dose, followed by 6 mg/kg every 3 weeks in combination with intravenous docetaxel, 75 mg/m2, every 3 weeks and intravenous carboplatin area under the curve of 6 every 3 weeks for 6 cycles, or this regimen plus intravenous pertuzumab, 840 mg, loading dose, followed by an intravenous 420-mg dose every 3 weeks for 6 cycles., Main Outcome and Measures: Association of baseline assay-reported pathologic complete response (pCR) score with pCR in the breast and axilla, as well as association of baseline assay-reported pCR score with response to pertuzumab., Results: The assay was evaluated in 155 patients with ERBB2-positive breast cancer (mean [range] age, 50.3 [26-78] years). Clinical T1 to T2 and node-positive disease was present in 113 (72.9%) and 99 (63.9%) patients, respectively, and 105 (67.7%) tumors were hormone receptor positive. The overall pCR rate was 57.4% (95% CI, 49.2%-65.2%). The proportion of patients in the assay-reported pCR-low, pCR-medium, and pCR-high groups was 53 (34.2%), 54 (34.8%), and 48 (31.0%), respectively. In the multivariable analysis, the assay-reported pCR score (as a continuous variable from 0-100) showed a statistically significant association with pCR (odds ratio [OR] per 10-unit increase, 1.43; 95% CI, 1.22-1.70; P < .001). The pCR rates in the assay-reported pCR-high and pCR-low groups were 75.0% and 28.3%, respectively (OR, 7.85; 95% CI, 2.67-24.91; P < .001). In the combined analysis (n = 282), an increase in pCR rate due to pertuzumab was found in the assay-reported pCR-high tumors (OR, 5.36; 95% CI, 1.89-15.20; P < .001) but not in the assay-reported pCR-low tumors (OR, 0.86; 95% CI, 0.30-2.46; P = .77). A statistically significant interaction between the assay-reported pCR score and the effect of pertuzumab in pCR was observed., Conclusions and Relevance: This diagnostic/prognostic study demonstrated that the genomic assay predicted pCR following neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab. This assay could guide therapeutic decisions regarding the use of neoadjuvant pertuzumab.
- Published
- 2023
- Full Text
- View/download PDF
26. A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol.
- Author
-
Lemos R, Areias-Marques S, Ferreira P, O'Brien P, Beltrán-Jaunsarás ME, Ribeiro G, Martín M, Del Monte-Millán M, López-Tarruella S, Massarrah T, Luís-Ferreira F, Frau G, Venios S, McManus G, and Oliveira-Maia AJ
- Subjects
- Humans, Quality of Life, Artificial Intelligence, Prospective Studies, Anxiety psychology, Treatment Outcome, Observational Studies as Topic, Depression psychology, Neoplasms complications, Neoplasms therapy
- Abstract
Background: Depression is a common condition among cancer patients, across several points in the disease trajectory. Although presenting higher prevalence rates than the general population, it is often not reported or remains unnoticed. Moreover, somatic symptoms of depression are common in the oncological context and should not be dismissed as a general symptom of cancer. It becomes even more challenging to track psychological distress in the period after the treatment, where connection with the healthcare system typically becomes sporadic. The main goal of the FAITH project is to remotely identify and predict depressive symptoms in cancer survivors, based on a federated machine learning (ML) approach, towards optimization of privacy., Methods: FAITH will remotely analyse depression markers, predicting their negative trends. These markers will be treated in distinct categories, namely nutrition, sleep, activity and voice, assessed in part through wearable technologies. The study will include 300 patients who have had a previous diagnosis of breast or lung cancer and will be recruited 1 to 5 years after the end of primary cancer. The study will be organized as a 12-month longitudinal prospective observational cohort study, with monthly assessments to evaluate depression symptoms and quality of life among cancer survivors. The primary endpoint is the severity of depressive symptoms as measured by the Hamilton Depression Rating Scale (Ham-D) at months 3, 6, 9 and 12. Secondary outcomes include self-reported anxiety and depression symptoms (HADS scale), and perceived quality of life (EORTC questionnaires), at baseline and monthly. Based on the predictive models gathered during the study, FAITH will also aim at further developing a conceptual federated learning framework, enabling to build machine learning models for the prediction and monitoring of depression without direct access to user's personal data., Discussion: Improvements in the objectivity of psychiatric assessment are necessary. Wearable technologies can provide potential indicators of depression and anxiety and be used for biofeedback. If the FAITH application is effective, it will provide healthcare systems with a novel and innovative method to screen depressive symptoms in oncological settings., Trial Registration: Trial ID: ISRCTN10423782 . Date registered: 21/03/2022., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
27. Role of germline variants in the metastasis of breast carcinomas.
- Author
-
Santonja Á, Moya-García AA, Ribelles N, Jiménez-Rodríguez B, Pajares B, Fernández-De Sousa CE, Pérez-Ruiz E, Del Monte-Millán M, Ruiz-Borrego M, de la Haba J, Sánchez-Rovira P, Romero A, González-Neira A, Lluch A, and Alba E
- Subjects
- Breast Neoplasms genetics, Genome-Wide Association Study, Humans, Tumor Microenvironment, Germ-Line Mutation, Neoplasm Metastasis
- Abstract
Most cancer-related deaths in breast cancer patients are associated with metastasis, a multistep, intricate process that requires the cooperation of tumour cells, tumour microenvironment and metastasis target tissues. It is accepted that metastasis does not depend on the tumour characteristics but the host's genetic makeup. However, there has been limited success in determining the germline genetic variants that influence metastasis development, mainly because of the limitations of traditional genome-wide association studies to detect the relevant genetic polymorphisms underlying complex phenotypes. In this work, we leveraged the extreme discordant phenotypes approach and the epistasis networks to analyse the genotypes of 97 breast cancer patients. We found that the host's genetic makeup facilitates metastases by the dysregulation of gene expression that can promote the dispersion of metastatic seeds and help establish the metastatic niche-providing a congenial soil for the metastatic seeds., Competing Interests: CONFLICTS OF INTEREST The authors declare no conflict of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results., (Copyright: © 2022 Santonja et al.)
- Published
- 2022
- Full Text
- View/download PDF
28. HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping.
- Author
-
Bueno Muiño C, Martín M, Del Monte-Millán M, García-Saénz JÁ, and López-Tarruella S
- Abstract
Long-term outcomes in breast cancer patients differ based on the molecular subtype, with HER2-E being the most aggressive one. Advances in clinical practice have dramatically shifted HER2+ breast cancer prognosis. Risk adapted strategies to individualize therapies are necessary. De-escalation approaches have been encouraged based on the risks of clinical-pathological factors. Molecular gene subtyping could further accurately define HER2 addicted tumours that are sensitive to anti-HER2 therapies, thus sparing unnecessary treatments. The transition from immunochemistry to molecular profiling in HER2+ breast cancer is discussed.
- Published
- 2022
- Full Text
- View/download PDF
29. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
- Author
-
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, and Symmans WF
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Breast Neoplasms pathology, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Neoadjuvant Therapy, Neoplasm, Residual, Receptor, ErbB-2 analysis, Young Adult, Breast Neoplasms drug therapy, Breast Neoplasms mortality
- Abstract
Background: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across different phenotypic subtypes of breast cancer, to assess generalisability in a broad range of practice settings., Methods: In this pooled analysis, 12 institutes and trials in Europe and the USA were identified by personal communications with site investigators. We obtained participant-level RCB results, and data on clinical and pathological stage, tumour subtype and grade, and treatment and follow-up in November, 2019, from patients (aged ≥18 years) with primary stage I-III breast cancer treated with neoadjuvant chemotherapy followed by surgery. We assessed the association between the continuous RCB score and the primary study outcome, event-free survival, using mixed-effects Cox models with the incorporation of random RCB and cohort effects to account for between-study heterogeneity, and stratification to account for differences in baseline hazard across cancer subtypes defined by hormone receptor status and HER2 status. The association was further evaluated within each breast cancer subtype in multivariable analyses incorporating random RCB and cohort effects and adjustments for age and pretreatment clinical T category, nodal status, and tumour grade. Kaplan-Meier estimates of event-free survival at 3, 5, and 10 years were computed for each RCB class within each subtype., Findings: We analysed participant-level data from 5161 patients treated with neoadjuvant chemotherapy between Sept 12, 1994, and Feb 11, 2019. Median age was 49 years (IQR 20-80). 1164 event-free survival events occurred during follow-up (median follow-up 56 months [IQR 0-186]). RCB score was prognostic within each breast cancer subtype, with higher RCB score significantly associated with worse event-free survival. The univariable hazard ratio (HR) associated with one unit increase in RCB ranged from 1·55 (95% CI 1·41-1·71) for hormone receptor-positive, HER2-negative patients to 2·16 (1·79-2·61) for the hormone receptor-negative, HER2-positive group (with or without HER2-targeted therapy; p<0·0001 for all subtypes). RCB score remained prognostic for event-free survival in multivariable models adjusted for age, grade, T category, and nodal status at baseline: the adjusted HR ranged from 1·52 (1·36-1·69) in the hormone receptor-positive, HER2-negative group to 2·09 (1·73-2·53) in the hormone receptor-negative, HER2-positive group (p<0·0001 for all subtypes)., Interpretation: RCB score and class were independently prognostic in all subtypes of breast cancer, and generalisable to multiple practice settings. Although variability in hormone receptor subtype definitions and treatment across patients are likely to affect prognostic performance, the association we observed between RCB and a patient's residual risk suggests that prospective evaluation of RCB could be considered to become part of standard pathology reporting after neoadjuvant therapy., Funding: National Cancer Institute at the US National Institutes of Health., Competing Interests: Declaration of interests AKG reports personal fees from Sinochips Diagnostics. CC reports institutional funding from Genentech, Roche, Servier, and AstraZeneca; and participation in a data and safety monitoring advisory board for iMED External Science Panel. CY reports institutional funding from Quantum Leap Healthcare Collaborative. DC reports institutional research funding from Novartis, AstraZeneca, Pfizer, Roche, Eli-Lilly, Puma Biotechnology, Daiichi Sankyo, Synthon, Seagen, Zymeworks, Elsevier, European Cancer Organisation, Celgene, Succinct Medical Communications, Prima BioMed (now Immutep), Oncolytics Biotech (US), Celldex Therapeutics, San Antonio Breast Cancer Consortium, Highfield Communication, Samsung Bioepis, prIME Oncology, Merck Sharp & Dohme, Prima BioMed (now Immutep), RTI Health Solutions, and Eisai. WFS owns stocks in Delphi Diagnostics; and reports the patent “method of measuring residual cancer and predicting patient survival” (US Patent and Trademark Office [USPTO] number 7711494B2). GSS reports institutional research funding from AstraZeneca, Merck, Novartis, and Roche. HE reports institutional research funding from Roche Sanofi-Aventis; is a consultant for Daiichi-Sankyo, AstraZeneca, Intas Pharmaceuticals, and prIME Oncology; and reports travel support from Daiichi-Sankyo, AstraZeneca, Intas Pharmaceuticals, Pfizer, and Amgen. JEA reports institutional research funding from AstraZeneca; and honoraria from Pfizer and Eisai. JMSB reports grants from Thermo Fisher Scientific, Geoptix, Agendia, NanoString Technologies, Stratifyer, and Biotheranostics; is a consultant for Insight Genetics, BioNTech, Biotheranostics, Pfizer, RNA Diagnostics, and OncoXchange; reports honoraria from NanoString Technology, Oncology Education, and Biotheranostics; reports travel support from Biotheranostics and Nanostring Technologies; reports patents “histone gene module predicts anthracycline benefit” (Patent Cooperation Treaty [PCT] number CA2016/000247); “95-gene signature of residual risk following endocrine treatment” (PCT number CA2016/000304); “immune gene signature predicts anthracycline benefit” (PCT number CA2016/000305); and applied for patents “methods and devices for predicting anthracycline treatment efficacy” (USPTO application number 15/325,472; European Patent Office number 15822898.1; Canada, not yet assigned) and “systems, devices and methods for constructing and using a biomarker” (USPTO application number 15/328,108; European Patent Office number 15824751.0; Canada, not yet assigned). JCB reports institutional research funding from Eli Lilly. LP is a consultant for and receives honoraria from AstraZeneca, Merck, Novartis, Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Almac, H3 Biomedicine, Clovis, and Syndax; and reports the patent “method of measuring residual cancer and predicting patient survival” (US Patent Number 7711494B2). LaH reports individual research grants from Roche and Sanofi-Aventis; and travel support from Roche, AstraZeneca, Pfizer, and Sanofi-Aventis. LJE reports institutional research funding from Merck; participation in an advisory board for Blue Cross Blue Shield; and personal fees from UpToDate. LJvV is an employee of and owns stock in Agendia. MPG reports individual research grants from Pfizer, Sermonix, and Eli Lilly; and is a consultant for Pfizer, Eli Lilly, Novartis, Biotheranostics, Sermonix, Context Therapeutics, and Eagle Therapeutics. MM reports grants from Roche, Puma, and Novartis; is a consultant for AstraZeneca, Amgen, Glaxo, Taiho Oncology, Roche, Novartis, PharmaMar, Eli Lilly, Puma Biotechnology, Daiichi Sankyo, and Pfizer; reports honoraria from AstraZeneca, Amgen, Roche, Novartis, and Pfizer; and reports personal fees from Pfizer and Eli Lilly. PS reports institutional research funding from Novartis, Merck, and Bristol Myers Squibb; and is a consultant for Merck, Novartis, Seattle Genetics, Gilead Immunomedics, AstraZeneca, and ExactSciences. SL-T has received consulting fees from AstraZeneca, Novartis, Roche, Pfizer, Celgene, Pierre-Fabre, Eisai, and Eli Lilly; reports honoraria from Eli Lilly; and reports travel support from Novartis, Celgene, Merck Sharp & Dohme, Roche, and Pfizer. SBE reports institutional research funding from Pfizer. All other authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
30. Technical Challenges for CTC Implementation in Breast Cancer.
- Author
-
Ramos-Medina R, López-Tarruella S, Del Monte-Millán M, Massarrah T, and Martín M
- Abstract
Breast cancer is the most common neoplasm in women worldwide. Tissue biopsy, currently the gold standard to obtain tumor molecular information, is invasive and might be affected by tumor heterogeneity rendering it incapable to portray the complete dynamic picture by the absence of specific genetic changes during the evolution of the disease. In contrast, liquid biopsy can provide unique opportunities for real-time monitoring of disease progression, treatment response and for studying tumor heterogeneity combining the information of DNA that tumors spread in the blood (circulating tumor DNA) with CTCs analysis. In this review, we analyze the technical and biological challenges for isolation and characterization of circulating tumor cells from breast cancer patients. Circulating tumor cell (CTC) enumeration value is included in numerous clinical studies due to the prognostic's role of these cells. Despite this, there are so many questions pending to answer. How to manage lymphocytes background, how to distinguish the CTCs subtypes or how to work with frozen samples, are some of the issues that will discuss in this review. Based on our experience, we try to address these issues and other technical limitations that should be solved to optimize the standardization of protocols, sample extraction procedures, circulating-tumor material isolation (CTCs vs. ctDNA) and the very diverse methodologies employed, aiming to consolidate the use of CTCs in the clinic. Furthermore, we think that new approaches focusing on isolation CTCs in other body fluids such as cerebrospinal or ascitic fluid are necessary to increase the opportunities of circulating tumor cells in the practice clinic as well as to study the promising role of CTC clusters and their prognostic value in metastatic breast cancer.
- Published
- 2021
- Full Text
- View/download PDF
31. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
- Author
-
Escudero-Vilaplana V, Collado-Borrell R, Del Monte-Millán M, Hoyo-Muñoz A, Gómez Martínez-Sagrera P, Revuelta-Herrero JL, Marzal-Alfaro B, Gonzalez-Haba E, López-Tarruella Cobo S, Jerez Gilarranz Y, Herranz A, Sanjurjo M, and Martin M
- Subjects
- Female, Humans, Incidence, Longitudinal Studies, Male, Prospective Studies, Risk Factors, Antineoplastic Agents adverse effects, Diarrhea chemically induced
- Abstract
Background: Diarrhea is one of the most frequent class adverse events associated with targeted oral antineoplastic agents (OAAs). Our objective was to analyze the incidence, characteristics, and severity of diarrhea in cancer patients in clinical practice., Methods: An observational, longitudinal, and prospective study of cancer outpatients treated with targeted OAAs was carried out in a tertiary hospital. Targed OAAs analyzed were anaplastic lymphoma kinase inhibitors, BCR-ABL inhibitors, cyclin-dependent kinase inhibitors, epidermal growth factor receptor inhibitors, mTOR inhibitors, poly (ADP-ribose) polymerase inhibitors, and vascular endothelial growth factor receptor inhibitors. Patients were given a data collection form to record daily the number, severity (CTCAE version 5.0), and characteristics of stools during the first 30 days of treatment with OAAs. Multivariate analysis was performed to identify risk factors associated with the incidence of diarrhea., Results: We analyzed 240 patients, of whom 28.7% experienced diarrhea (25.4% grades 1-2 and 3.3% grades 3-4). Patients treated with EGFR and VEGFR inhibitors had a higher incidence of diarrhea. The multivariate analysis revealed that taking the OAA with food was associated with a lower risk of diarrhea (OR = 0.404 [0.205-0.956], p = 0.038)., Conclusions: More than a third of patients in treatment with OAAs presented diarrhea (any grade), and 22.1% of stools were semi-liquid/liquid. In multivariate analysis, taking the OAA on an empty stomach was associated with a statistically significant increase in the incidence of diarrhea.
- Published
- 2021
- Full Text
- View/download PDF
32. Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid.
- Author
-
Calles A, Aparicio MI, Alva M, Bringas M, Gutierrez N, Soto J, Arregui M, Tirado VC, Álvarez EL, Del Monte-Millán M, Massarrah T, Galera M, Álvarez R, and Martín M
- Abstract
Background: Cancer patients represent a vulnerable population for COVID-19 illness. We aimed to analyze outcomes of lung cancer patients affected by COVID-19 in a tertiary hospital of a high-incidence region during the pandemic. Methods: We annotated 23 lung cancer patients consecutively diagnosed with COVID-19 at our institution (HGUGM; Madrid, Spain) between March 4th, 2020 and May 12th, 2020. Only patients with a confirmatory SARS-CoV-2 RT-PCR were included in the study. Results: All patients had at least 1 COVID-19 related symptom; cough (48%), shortness of breath (48%), fever (39%), and low-grade fever (30%) were the most common. Time from symptoms onset to first positive SARS-CoV-2 PCR was 5.5 days (range 1-17), with 13% of cases needed from a 2nd PCR to confirm diagnosis. There was a high variability on thoracic imaging findings, with multilobar pneumonia as the most commonly found pattern (74%). Main lab test abnormalities were low lymphocytes count (87%), high neutrophil to lymphocyte ratio -NLR- (78%), and elevated inflammatory markers: fibrinogen (91%), c-reactive protein -CRP- (87%), and D-dimer (70%). In our series, hospitalization rate was 74%, 39% of patients developed acute respiratory distress syndrome (ARDS), and the case-fatality rate was 35% (8/23). 87% of patients received anti-viral treatment (87% hydroxychloroquine, 74% lopinavir/ritonavir, 13% azithromycin), 43% corticosteroids, 26% interferon-β, 4% tocilizumab, and 82% of hospitalized patients received anticoagulation. High-oxygen requirements were needed in 39% of patients, but only 1 pt was admitted for invasive MV and was discharged 42 days after admission. Multiple variables related to tumor status, clinical baseline conditions, and inflammation markers were associated with mortality but did not remain statistically significant in a multivariate model. In patients with lung cancer receiving systemic therapy ( n = 242) incidence and mortality from COVID-19 were 4.5, and 2.1%, respectively, with no differences found by type of treatment. Conclusions: Lung cancer patients represent a vulnerable population for COVID-19, according to the high rate of hospitalization, onset of ARDS, and high mortality rate. Although larger series are needed, no differences in mortality were found by type of cancer treatment. Measures to minimize the risk of SARS-CoV-2 infection remain key to protect lung cancer patients., (Copyright © 2020 Calles, Aparicio, Alva, Bringas, Gutierrez, Soto, Arregui, Tirado, Álvarez, del Monte-Millán, Massarrah, Galera, Álvarez and Martín.)
- Published
- 2020
- Full Text
- View/download PDF
33. Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer.
- Author
-
Núñez-Torres R, Martín M, García-Sáenz JÁ, Rodrigo-Faus M, Del Monte-Millán M, Tejera-Pérez H, Pita G, de la Torre-Montero JC, Pinilla K, Herraez B, Peiró-Chova L, Bermejo B, Lluch A, and González-Neira A
- Subjects
- ATP Binding Cassette Transporter, Subfamily B genetics, Adult, Age Factors, Alopecia chemically induced, Alopecia epidemiology, Alopecia pathology, Biopsy, Case-Control Studies, Dose-Response Relationship, Drug, Enhancer Elements, Genetic genetics, Female, Follow-Up Studies, Genetic Predisposition to Disease, Genome-Wide Association Study, Hair Follicle drug effects, Hair Follicle pathology, Humans, Middle Aged, Polymorphism, Single Nucleotide, Promoter Regions, Genetic genetics, Retrospective Studies, Risk Factors, Alopecia genetics, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms drug therapy, Docetaxel adverse effects
- Abstract
Importance: Persistent chemotherapy-induced alopecia (pCIA) has been recently described in patients with breast cancer and in its most severe form occurs in up to 10% of these patients. Genetic risk factors associated with pCIA have not been adequately explored., Objective: To identify genetic variants associated with pCIA., Design, Setting, and Participants: In this genetic association study, 215 women with breast cancer treated with docetaxel-based chemotherapy with a follow-up of 1.5 to 10 years after the end of the treatment were recruited retrospectively through 3 hospital oncology units across Spain between 2005 and 2018. Severe pCIA was defined as lack of scalp hair recovery (Common Terminology Criteria for Adverse Events, version 3.0, grade 2) 18 months or more after the end of treatment. Patients with grade 2 pCIA were selected as cases, and those with no sign of residual alopecia 12 months after the end of docetaxel treatment were selected as controls. A genome-wide association study in a discovery phase was conducted, and logistic regression was used to identify variants associated with the risk to develop this adverse effect. The validity of the association was addressed through a replication phase., Exposures: Docetaxel-based chemotherapy., Main Outcomes and Measures: Genotypes of single-nucleotide variants associated with pCIA., Results: In total, 215 women with breast cancer (median age, 51.6 years; interquartile range, 44-60 years) were recruited (173 patients for the discovery phase and 42 patients for the replication phase). In the discovery phase, ABCB1 genetic variants were associated with risk to develop pCIA. In particular, single-nucleotide variation rs1202179, a regulatory variant located in an enhancer element that interacts with the ABCB1 promoter, was associated with the occurrence of pCIA. This finding was validated in the replication cohort (combined odds ratio, 4.05; 95% CI, 2.46-6.67; P = 3.946 × 10-8). This variant is associated with ABCB1 mRNA expression, and the risk allele was associated with decreased ABCB1 expression levels (P = 1.64 × 10-20)., Conclusions and Relevance: This is the first study, to our knowledge, that identifies an association between a regulatory variant in the ABCB1 gene and the occurrence of pCIA in patients with breast cancer who were treated with docetaxel-based therapies. This finding suggests an important insight into the biological mechanisms underlying pCIA and opens the opportunity to explore personalized treatment of these patients.
- Published
- 2020
- Full Text
- View/download PDF
34. Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study.
- Author
-
Moreno F, Gayarre J, López-Tarruella S, Del Monte-Millán M, Picornell AC, Álvarez E, García-Saenz JÁ, Jerez Y, Márquez-Rodas I, Echavarría I, Palomero M, Bueno C, Aragón Bodí AM, Muñoz MS, González Del Val R, Bueno O, Cebollero-Presmanes M, Ocaña I, Arias A, Romero P, Massarrah T, Ramos-Medina R, and Martín M
- Abstract
Purpose: Genetic heterogeneity between primary tumors and their metastatic lesions has been documented in several breast cancer studies. However, the selection of therapy for patients with metastatic breast cancer and the search for biomarkers for targeted therapy are often based on findings from the primary tumor, mainly because of the difficulty of distant metastasis core biopsies. New methods for monitoring genomic changes in metastatic breast cancer are needed (ie, circulating tumor DNA [ctDNA] genomic analysis). The objectives of this study were to assess the concordance of genomic variants between primary and metastatic tumor tissues and the sensitivity of plasma ctDNA analysis to identify variants detected in tumor biopsies., Patients and Methods: Next-generation sequencing technology was used to assess the genomic mutation profile of a panel of 54 cancer genes in matched samples of primary tumor, metastatic tumor, and plasma from 40 patients with metastatic breast cancer., Results: Using Ion Torrent technology (ThermoFisher Scientific, Waltham, MA), we identified 110 variants that were common to the primary and metastatic tumors. ctDNA analysis had a sensitivity of 0.972 in detecting variants present in both primary and metastatic tissues. In addition, we identified 13 variants in metastatic tissue and ctDNA not present in primary tumor., Conclusion: We identified genomic variants present in metastatic biopsies and plasma ctDNA that were not present in the primary tumor. Deep sequencing of plasma ctDNA detected most DNA variants previously identified in matched primary and metastatic tissues. ctDNA might aid in therapy selection and in the search for biomarkers for drug development in metastatic breast cancer.
- Published
- 2019
- Full Text
- View/download PDF
35. Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
- Author
-
González-Rivera M, Lobo M, López-Tarruella S, Jerez Y, Del Monte-Millán M, Massarrah T, Ramos-Medina R, Ocaña I, Picornell A, Santillán Garzón S, Pérez-Carbornero L, García-Saenz JA, Gómez H, Moreno F, Márquez-Rodas I, Fuentes H, and Martin M
- Published
- 2017
- Full Text
- View/download PDF
36. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
- Author
-
Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, and Martin M
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carboplatin administration & dosage, Carboplatin adverse effects, Carcinoma genetics, Carcinoma therapy, Case-Control Studies, Combined Modality Therapy, Docetaxel, Female, Filgrastim therapeutic use, Genes, BRCA1, Genes, BRCA2, Humans, Kansas, Mastectomy, Middle Aged, Multicenter Studies as Topic, Observational Studies as Topic, Polyethylene Glycols therapeutic use, Prospective Studies, Spain, Taxoids administration & dosage, Taxoids adverse effects, Treatment Outcome, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma drug therapy, Neoadjuvant Therapy, Triple Negative Breast Neoplasms drug therapy
- Abstract
Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum combinations in TNBC is not well known. Here, we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC., Experimental Design: The study population includes 190 patients with stage I-III TNBC treated uniformly on two independent prospective cohorts. All patients were prescribed NA chemotherapy regimen of carboplatin (AUC 6) + docetaxel (75 mg/m
2 ) given every 21 days × 6 cycles. pCR (no evidence of invasive tumor in the breast and axilla) and residual cancer burden (RCB) were evaluated., Results: Among 190 patients, median tumor size was 35 mm, 52% were lymph node positive, and 16% had germline BRCA1/2 mutation. The overall pCR and RCB 0 + 1 rates were 55% and 68%, respectively. pCRs in patients with BRCA-associated and wild-type TNBC were 59% and 56%, respectively (P = 0.83). On multivariable analysis, stage III disease was the only factor associated with a lower likelihood of achieving a pCR. Twenty-one percent and 7% of patients, respectively, experienced at least one grade 3 or 4 adverse event., Conclusions: The CbD regimen was well tolerated and yielded high pCR rates in both BRCA-associated and wild-type TNBC. These results are comparable with pCR achieved with the addition of carboplatin to anthracycline-taxane chemotherapy. Our study adds to the existing data on the efficacy of platinum agents in TNBC and supports further exploration of the CbD regimen in randomized studies. Clin Cancer Res; 23(3); 649-57. ©2016 AACR., Competing Interests: Authors’ Disclosures of Potential Conflicts of Interest No potential conflicts of interest for all of the authors, (©2016 American Association for Cancer Research.)- Published
- 2017
- Full Text
- View/download PDF
37. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
- Author
-
González-Rivera M, Lobo M, López-Tarruella S, Jerez Y, Del Monte-Millán M, Massarrah T, Ramos-Medina R, Ocaña I, Picornell A, Santillán Garzón S, Pérez-Carbornero L, García-Saenz JA, Gómez H, Moreno F, Márquez-Rodas I, Fuentes H, and Martin M
- Subjects
- Adult, Carboplatin therapeutic use, Clinical Trials as Topic, Docetaxel, Female, Genetic Predisposition to Disease, Humans, Middle Aged, Neoadjuvant Therapy methods, Prospective Studies, Taxoids therapeutic use, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms genetics, BRCA1 Protein genetics, BRCA2 Protein genetics, Germ-Line Mutation, Triple Negative Breast Neoplasms pathology, Tumor Suppressor Proteins genetics, Ubiquitin-Protein Ligases genetics
- Abstract
We describe the status and frequency of germline DNA genetic findings in an unselected prospective cohort of triple negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Study population includes 124 consecutive patients with stage II-III TNBC from a trial exploring the antitumor activity of neoadjuvant carboplatin/docetaxel chemotherapy enrolled between 2012 and March 2015, to determine the frequency of germline DNA genetic mutations. 17.1 % of the patients with germline DNA tested had deleterious mutations in any of the analyzed genes (12.38 % in BRCA1, 1.9 % in BRCA2 and BARD1 and 0.95 % in RAD51D). Attending the intrinsic subtype, all the BRCA1/2 carriers tested had basal-like subtype. Among wild-type (WT) patients, 70.11 % had basal subtype, 16.09 % HER2 enriched, 1.15 % Luminal B, and 4.60 % Normal-like. Mean age at diagnosis was significantly lower in mutation-carriers compared with no carriers (43.72 vs 53.10, p = 0.004). 3 BRCA1/2 carriers were detected between 51 and 60 years, and only one deleterious mutation (BARD1) over 60 years. A positive familiar history of breast and ovarian cancer was more frequent in patients with deleterious mutations (39.39 vs 17.94 %, p = 0.043). Our study confirms the prevalence of BRCA1/2 mutations in TNBC patients. TNBC should therefore be considered by itself as a criterion for BRCA1/2 genetic testing. Determination of other breast cancer predisposition genes implicated in homologous recombination should also be discussed in this population. However, no definitive conclusions can be reached due to the low prevalence and the uncertain clinical impact of most of the genes included.
- Published
- 2016
- Full Text
- View/download PDF
38. Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib.
- Author
-
Domínguez JM, Fuertes A, Orozco L, del Monte-Millán M, Delgado E, and Medina M
- Subjects
- Administration, Oral, Alzheimer Disease drug therapy, Alzheimer Disease enzymology, Animals, Cell Line, Clinical Trials, Phase II as Topic, Enzyme Inhibitors therapeutic use, Glycogen Synthase Kinase 3 genetics, Glycogen Synthase Kinase 3 metabolism, Glycogen Synthase Kinase 3 beta, Humans, Spodoptera, Structure-Activity Relationship, Enzyme Inhibitors chemistry, Glycogen Synthase Kinase 3 antagonists & inhibitors, Glycogen Synthase Kinase 3 chemistry
- Abstract
Tideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer disease and progressive supranuclear palsy. Sustained oral administration of the compound to a variety of animal models decreases Tau hyperphosphorylation, lowers brain amyloid plaque load, improves learning and memory, and prevents neuronal loss. We report here that tideglusib inhibits GSK-3β irreversibly, as demonstrated by the lack of recovery in enzyme function after the unbound drug has been removed from the reaction medium and the fact that its dissociation rate constant is non-significantly different from zero. Such irreversibility may explain the non-competitive inhibition pattern with respect to ATP shown by tideglusib and perhaps other structurally related compounds. The replacement of Cys-199 by an Ala residue in the enzyme seems to increase the dissociation rate, although the drug retains its inhibitory activity with decreased potency and long residence time. In addition, tideglusib failed to inhibit a series of kinases that contain a Cys homologous to Cys-199 in their active site, suggesting that its inhibition of GSK-3β obeys to a specific mechanism and is not a consequence of nonspecific reactivity. Results obtained with [(35)S]tideglusib do not support unequivocally the existence of a covalent bond between the drug and GSK-3β. The irreversibility of the inhibition and the very low protein turnover rate observed for the enzyme are particularly relevant from a pharmacological perspective and could have significant implications on its therapeutic potential.
- Published
- 2012
- Full Text
- View/download PDF
39. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
- Author
-
Hamann M, Alonso D, Martín-Aparicio E, Fuertes A, Pérez-Puerto MJ, Castro A, Morales S, Navarro ML, Del Monte-Millán M, Medina M, Pennaka H, Balaiah A, Peng J, Cook J, Wahyuono S, and Martínez A
- Subjects
- Animals, Combinatorial Chemistry Techniques, Glycogen Synthase Kinase 3 beta, Humans, Indonesia, Molecular Structure, Structure-Activity Relationship, Alkaloids chemistry, Alzheimer Disease drug therapy, Carbazoles chemistry, Glycogen Synthase Kinase 3 antagonists & inhibitors, Porifera chemistry
- Abstract
Manzamine A and related derivatives isolated from a common Indonesian sponge, Acanthostrongylophora, have been identified as a new class of GSK-3beta inhibitors. The semisynthesis of new analogues and the first structure-activity relationship studies with GSK-3beta are also reported. Moreover, manzamine A proved to be effective in decreasing tau hyperphosphorylation in human neuroblastoma cell lines, a demonstration of its ability to enter cells and interfere with tau pathology. Inhibition studies of manzamine A against a selected panel of five different kinases related to GSK-3beta, specifically CDK-1, PKA, CDK-5, MAPK, and GSK-3alpha, show the specific inhibition of manzamine A on GSK-3beta and CDK-5, the two kinases involved in tau pathological hyperphosphorylation. These results suggest that manzamine A constitutes a promising scaffold from which more potent and selective GSK-3 inhibitors could be designed as potential therapeutic agents for Alzheimer's disease.
- Published
- 2007
- Full Text
- View/download PDF
40. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD.
- Author
-
del Monte-Millán M, García-Palomero E, Valenzuela R, Usán P, de Austria C, Muñoz-Ruiz P, Rubio L, Dorronsoro I, Martínez A, and Medina M
- Subjects
- Acetylcholinesterase metabolism, Alzheimer Disease enzymology, Humans, Kinetics, Tacrine analogs & derivatives, Tacrine pharmacokinetics, Alzheimer Disease drug therapy, Cholinesterase Inhibitors pharmacokinetics, Cholinesterase Inhibitors therapeutic use
- Abstract
The therapeutic potential of acetylcholinesterase (AChE) inhibitors has been strengthened recently by evidence showing that besides their role in cognitive function, they might contribute to slow down the neurodegeneration in Alzheimer's disease (AD) patients. It is known that AChE exerts secondary noncholinergic functions, related to its peripheral anionic site, in cell adhesion and differentiation, and recent findings also support its role in mediating the processing and deposition of beta-amyloid (Abeta) peptide. AChE is one of the proteins that colocalizes with Abeta peptide deposits in the brain of AD patients and promotes Abeta fibrillogenesis by forming stable AChEA beta complexes. Additionally, it has also been postulated that AChE binds through its peripheral site to the Abeta nonamyloidogenic form and acts as a pathological chaperone inducing a conformational transition to the amyloidogenic form (Inestrosa et al., 1996; Bartolini et al., 2003). Anew series of dual binding site AChE inhibitors has been designed and synthesized as new potent AChE inhibitors, which might simultaneously alleviate cognitive deficits and behave as disease-modifying agents by inhibiting Abeta peptide aggregation through binding to both catalytic and peripheral sites of the enzyme.
- Published
- 2006
- Full Text
- View/download PDF
41. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
- Author
-
Muñoz-Ruiz P, Rubio L, García-Palomero E, Dorronsoro I, del Monte-Millán M, Valenzuela R, Usán P, de Austria C, Bartolini M, Andrisano V, Bidon-Chanal A, Orozco M, Luque FJ, Medina M, and Martínez A
- Subjects
- Amyloid beta-Peptides chemistry, Animals, Binding Sites, Butyrylcholinesterase chemistry, Cattle, Cell Line, Tumor, Cholinesterase Inhibitors chemistry, Cholinesterase Inhibitors toxicity, Dimerization, Drug Design, Erythrocytes enzymology, Fluorometry, Humans, Models, Molecular, Nootropic Agents chemistry, Nootropic Agents toxicity, Protein Binding, Structure-Activity Relationship, Tacrine chemistry, Tacrine toxicity, Acetylcholinesterase chemistry, Alzheimer Disease drug therapy, Amyloid beta-Peptides antagonists & inhibitors, Cholinesterase Inhibitors chemical synthesis, Nootropic Agents chemical synthesis, Tacrine analogs & derivatives, Tacrine chemical synthesis
- Abstract
New dual binding site acetylcholinesterase (AChE) inhibitors have been designed and synthesized as new potent drugs that may simultaneously alleviate cognitive deficits and behave as disease-modifying agents by inhibiting the beta-amyloid (A beta) peptide aggregation through binding to both catalytic and peripheral sites of the enzyme. Particularly, compounds 5 and 6 emerged as the most potent heterodimers reported so far, displaying IC50 values for AChE inhibition of 20 and 60 pM, respectively. More importantly, these dual AChE inhibitors inhibit the AChE-induced A beta peptide aggregation with IC50 values 1 order of magnitude lower than that of propidium, thus being the most potent derivatives with this activity reported up to date. We therefore conclude that these compounds are very promising disease-modifying agents for the treatment of Alzheimer's disease (AD).
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.